TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2013

SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.

R Campo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.